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ABSTRACT
RAF inhibitor monotherapy is ineffective in BRAF-mutant colorectal cancer (CRC) but RAF inhibitor
combinations have demonstrated improved efﬁcacy, likely through superior suppression of MAPK
signaling. The ﬁrst identiﬁed mechanisms of acquired resistance to these combinations all promote MAPK
reactivation, underscoring the MAPK pathway as a critical target in BRAF-mutant CRC. KEYWORDS
Clinical trials; colorectal
cancer; BRAF; BRAF inhibitor;
ERK inhibitor; MAPK;
resistance
Activating mutations in BRAF occur in approximately 10% of
colorectal cancers (CRCs)1 and trigger constitutive activation
of the mitogen-activated protein kinase (MAPK) pathway.
Notably, BRAF mutations in CRC confer a poor prognosis,2
therefore improved therapies for these patients are needed.
RAF inhibitor monotherapy has been effective in BRAF-
mutant melanoma, producing response rates of approximately
50–80%.3 However, the same treatment in BRAF-mutant CRC
yielded a response rate of only 5%.4 This difference in sensitiv-
ity suggests that resistance in BRAF-mutant CRC is driven by
unique signals. Deﬁning these resistance signals may reveal
opportunities to improve therapy.
Initially, it was hypothesized that resistance to RAF inhibitor
monotherapy in BRAF-mutant CRC suggested a lower depen-
dence on MAPK signaling, possibly through activation of a par-
allel signaling pathway. However, comparisons between BRAF-
mutant melanoma and CRC cell lines revealed that RAF inhibi-
tors led to sustained suppression of mitogen-activated protein
kinase (MAPK) signaling in melanoma cells, whereas CRCs
exhibited only transient suppression of the pathway.5,6 This
ﬁnding suggested that BRAF-mutant CRCs may still be depen-
dent on MAPK signaling, and that incomplete suppression by
RAF inhibitors may be the reason behind their lack of efﬁcacy
in CRC. Thus, therapeutic strategies capable of enhancing
MAPK suppression might have improved efﬁcacy in BRAF-
mutant CRC.
Studies by our group and others found that in many BRAF-
mutant CRCs, RAF inhibitor-induced reductions in MAPK sig-
naling lead to inactivation of negative feedback signals down-
stream of ERK, allowing epidermal growth factor receptor
(EGFR) to reactivate MAPK through RAS and CRAF5,7
(Fig. 1A, B). EGFR levels are higher in BRAF-mutant CRCs
than in melanomas, explaining why CRCs exhibit EGFR-medi-
ated resistance more frequently.
Since feedback reactivation of MAPK signaling is important
for resistance to RAF inhibitors in CRC, RAF-based inhibitor
combinations were tested in BRAF-mutant CRC laboratory
models, demonstrating reduced feedback activation and
improved MAPK suppression.5-7
Based on these data, clinical trials of RAF/MEK and RAF/
EGFR inhibitor combinations were initiated in patients with
BRAF-mutant CRC, yielding increased response rates of 12%,
and 13–26% respectively.8,9 However, although response rates
have improved, the efﬁcacy is still lower than in melanoma.
Importantly, evaluation of paired pre-treatment and on-treat-
ment biopsies revealed that, despite inhibition of multiple path-
way targets, the degree of MAPK inhibition achieved in patients
with BRAF-mutant CRC is less than that observed in patients
with melanoma treated with RAF inhibitor alone.8,9 These data
suggest that incomplete MAPK inhibition may still limit the
efﬁcacy of these combinations.
Another strategy currently in clinical trials for BRAF-
mutant CRC employs a combination of RAF/MEK/EGFR
inhibitors.9 Since not all MAPK feedback occurs through
EGFR, the addition of a MEK inhibitor may reduce path-
way reactivation and improve MAPK suppression. Indeed,
in patients receiving this therapy the degree of MAPK inhi-
bition is comparable to that achieved in BRAF-mutant mel-
anoma patients receiving RAF monotherapy.9 Initial
response rates with the triple combination are approxi-
mately 40%, demonstrating that greater MAPK suppression
can improve efﬁcacy in BRAF-mutant CRC.9
Recently, our group identiﬁed the ﬁrst mechanisms of clini-
cal acquired resistance to RAF inhibitor combinations in
patients with BRAF-mutant CRC. We investigated acquired
resistance to RAF/EGFR or RAF/MEK combinations in 3
patients who had initially responded to these therapies. To
identify new alterations that may be driving acquired
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resistance, a post-progression tumor biopsy was obtained and
compared to a paired pre-treatment tumor biopsy by whole-
exome and transcriptome sequencing. Strikingly, resistant
tumors in all 3 patients had developed alterations that reacti-
vated the MAPK pathway, once again highlighting the critical
dependence of BRAF-mutant CRC on MAPK signaling10
(Fig. 1C).
The ﬁrst patient progressed following an initial response to a
RAF/MEK combination and was switched to a RAF/EGFR
combination, on which one lesion grew rapidly throughout
therapy. Comparison of the post-RAF/EGFR biopsy with prior
biopsies revealed 25-fold ampliﬁcation of wild-type KRAS in
the progressing lesion that was not present in the earlier sam-
ples, implicating KRAS ampliﬁcation as the cause of acquired
resistance. Interestingly, in vitro modeling of acquired resis-
tance to RAF/EGFR or RAF/MEK in BRAF-mutant CRC cells
revealed that resistant lines had acquired activating mutations
in KRAS, supporting the notion that KRAS activation can drive
resistance to these therapies.
The second patient progressed after initially responding to a
RAF/EGFR combination. A post-progression tumor biopsy was
found to have high-level ampliﬁcation of the BRAFV600E allele,
which was not present in a pre-treatment biopsy from the same
lesion, as the likely resistance mechanism.
Whole-exome sequencing of post-progression biopsy from a
third patient following an initial response to RAF/MEK therapy
revealed the emergence of a MEK1F53L mutation that was
absent in the pre-treatment biopsy.
Laboratory studies conﬁrmed that each of the alterations
found in post-progression patient biopsies induced resis-
tance to either RAF/EGFR or RAF/MEK inhibitor combina-
tions by maintaining MAPK signaling despite therapy. This
ﬁnding further emphasizes that robust suppression of
MAPK signaling is critical for clinical beneﬁt in BRAF-
mutant CRC.
Importantly, for each identiﬁed mechanism of acquired
resistance, an ERK inhibitor retained the ability to suppress
MAPK signaling and could overcome the resistance. Together,
these data conﬁrm the critical dependence of BRAF-mutant
CRCs on MAPK signaling and suggest that ERK inhibitors
might become important components of future therapeutic
strategies for this disease.
Overall, an understanding of the resistance mechanisms
operant in BRAF-mutant CRC has led to improved response
rates in clinical trials over the past few years. Although addi-
tional pathways may play a role in resistance of BRAF-mutant
CRC, the data suggest that robust inhibition of MAPK signaling
is of primary importance. Targeted combination therapy
designed to more effectively block feedback reactivation of
MAPK signaling, perhaps through the incorporation of ERK
inhibitors, has the potential for improved clinical beneﬁt in
patients with this aggressive CRC subtype.
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